Ramosetron

Ramosetron

Ramosetron
Systematic (IUPAC) name
(1-methyl-1H-indol-3-yl)[(5R)-4,5,6,7-tetrahydro-1H-benzimidazol-5-yl]methanone
Clinical data
AHFS/Drugs.com
Routes of
administration
Intravenous
Pharmacokinetic data
Biological half-life 5.8 hours
Identifiers
CAS Registry Number  YesY
ATC code None
PubChem CID:
IUPHAR/BPS
ChemSpider  N
UNII  N
ChEMBL  N
Chemical data
Formula C17H17N3O
Molecular mass 279.33 g/mol
 N   

Ramosetron (INN) is a serotonin 5-HT3 receptor antagonist for the treatment of nausea and vomiting.[1] Ramosetron is also indicated for a treatment of “diarrhea-predominant irritable bowel syndrome in males”.[2] In India it is marketed under the brand name of "IBset".


It is only licensed for use in Japan and selected Southeast Asian countries. In Japan it is sold under the tradename Iribo (イリボー). [3] Elsewhere it is commonly sold under the tradename Nasea and in India as Nozia (300 mcg/ml Inj. & 100 mcg Tab.) [4]

References

  1. ^
  2. ^ http://www.astellas.com/en/corporate/news/detail/astellas-launches-irribow-for.html
  3. ^ Summary in Japanese. Retrieved on September 4, 2012.
  4. ^ Abridged prescribing information - Nasea (MIMS Philippines). Retrieved on June 13, 2008.